356 related articles for article (PubMed ID: 24392752)
1. Could chloramphenicol be used against ESKAPE pathogens? A review of in vitro data in the literature from the 21st century.
Čivljak R; Giannella M; Di Bella S; Petrosillo N
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):249-64. PubMed ID: 24392752
[TBL] [Abstract][Full Text] [Related]
2. Update on the main MDR pathogens: prevalence and treatment options.
Esposito S; De Simone G
Infez Med; 2017 Dec; 25(4):301-310. PubMed ID: 29286008
[TBL] [Abstract][Full Text] [Related]
3. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
[TBL] [Abstract][Full Text] [Related]
4. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
Kharat AS; Makwana N; Nasser M; Gayen S; Yadav B; Kumar D; Veeraraghavan B; Mercier C
Int J Antimicrob Agents; 2024 May; 63(5):107125. PubMed ID: 38431109
[TBL] [Abstract][Full Text] [Related]
5. Impact of an infectious diseases specialist-led antimicrobial stewardship programmes on antibiotic use and antimicrobial resistance in a large Korean hospital.
Hwang H; Kim B
Sci Rep; 2018 Oct; 8(1):14757. PubMed ID: 30283084
[TBL] [Abstract][Full Text] [Related]
6. Further increase of vancomycin-resistant Enterococcus faecium, amikacin- and fluoroquinolone-resistant Klebsiella pneumoniae, and imipenem-resistant Acinetobacter spp. in Korea: 2003 KONSAR surveillance.
Lee K; Park KH; Jeong SH; Lim HS; Shin JH; Yong D; Ha GY; Chong Y; KONSAR group
Yonsei Med J; 2006 Feb; 47(1):43-54. PubMed ID: 16502484
[TBL] [Abstract][Full Text] [Related]
7. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management.
Sandiumenge A; Rello J
Curr Opin Pulm Med; 2012 May; 18(3):187-93. PubMed ID: 22366995
[TBL] [Abstract][Full Text] [Related]
8. Intravenous colistin administration in neonates.
Jajoo M; Kumar V; Jain M; Kumari S; Manchanda V
Pediatr Infect Dis J; 2011 Mar; 30(3):218-21. PubMed ID: 21245777
[TBL] [Abstract][Full Text] [Related]
9. Evaluation of colistin as an agent against multi-resistant Gram-negative bacteria.
Li J; Nation RL; Milne RW; Turnidge JD; Coulthard K
Int J Antimicrob Agents; 2005 Jan; 25(1):11-25. PubMed ID: 15620821
[TBL] [Abstract][Full Text] [Related]
10. Alternatives for the treatment of infections caused by ESKAPE pathogens.
da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
[TBL] [Abstract][Full Text] [Related]
11. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
12. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
13. Recent trends in resistance to cell envelope-active antibacterial agents among key bacterial pathogens.
Master RN; Deane J; Opiela C; Sahm DF
Ann N Y Acad Sci; 2013 Jan; 1277():1-7. PubMed ID: 23346857
[TBL] [Abstract][Full Text] [Related]
14. Synergistic combinations of polymyxins.
Lenhard JR; Nation RL; Tsuji BT
Int J Antimicrob Agents; 2016 Dec; 48(6):607-613. PubMed ID: 27865626
[TBL] [Abstract][Full Text] [Related]
15. Risk factors associated with the isolation of colistin-resistant gram-negative bacteria: a matched case-control study.
Matthaiou DK; Michalopoulos A; Rafailidis PI; Karageorgopoulos DE; Papaioannou V; Ntani G; Samonis G; Falagas ME
Crit Care Med; 2008 Mar; 36(3):807-11. PubMed ID: 18431267
[TBL] [Abstract][Full Text] [Related]
16. Surveillance and comparison of antimicrobial susceptibility patterns of ESKAPE organisms isolated from patients with bacteraemia in South Africa, 2016 - 2017.
Ismail H; Lowman W; Govind CN; Swe Swe-Han K; Maloba MRB; Bamford C; Perovic O
S Afr Med J; 2019 Nov; 109(12):934-940. PubMed ID: 31865955
[TBL] [Abstract][Full Text] [Related]
17. In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens.
Michiels JE; Van den Bergh B; Verstraeten N; Fauvart M; Michiels J
Antimicrob Agents Chemother; 2016 Aug; 60(8):4630-7. PubMed ID: 27185802
[TBL] [Abstract][Full Text] [Related]
18. Measurement and prediction of antimicrobial resistance in bloodstream infections by ESKAPE pathogens and Escherichia coli.
De Socio GV; Rubbioni P; Botta D; Cenci E; Belati A; Paggi R; Pasticci MB; Mencacci A
J Glob Antimicrob Resist; 2019 Dec; 19():154-160. PubMed ID: 31112804
[TBL] [Abstract][Full Text] [Related]
19. In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomonas aeruginosa and Acinetobacter baumannii isolated from intensive care units.
Timurkaynak F; Can F; Azap OK; Demirbilek M; Arslan H; Karaman SO
Int J Antimicrob Agents; 2006 Mar; 27(3):224-8. PubMed ID: 16464562
[TBL] [Abstract][Full Text] [Related]
20. Economic burden of antibiotic resistance in ESKAPE organisms: a systematic review.
Zhen X; Lundborg CS; Sun X; Hu X; Dong H
Antimicrob Resist Infect Control; 2019; 8():137. PubMed ID: 31417673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
